罗格列酮对糖尿病大鼠血清MMP-9及外周血单核细胞MMP-9mRNA表达的影响

目的：观察过氧化物酶体增殖物激活受体γ（PPARγ）配体罗格列酮对糖尿病大鼠血清基质金属蛋白酶9（MMP-9）浓度和外周血单核细胞mRNA表达的影响。方法：30只SD大鼠随机分为三组，对照组、糖尿病组和罗格列酮组，每组10只。糖尿病组和罗格列酮组腹腔注射链脲霉素制作糖尿病大鼠模型后，罗格列酮组以罗格列酮灌胃，5mg·kg^-1·d^-1，共28d，对照组和糖尿病组以等量0.9％氯化钠溶液灌胃，比较治疗前、后的血清MMP-9浓度的变化，分离外周血单核细胞，RT-PCR检测MMP-9mRNA的变化。结果：处理28d后血清MMP-9浓度明显降低（P〈0.01），外周血单核细胞MMP-9mRNA表达量明显降低。结论：罗格列酮可以降低糖尿病大鼠血清MMP-9及外周血单核细胞MMP-9mRNA袁达．提示冀可能通过抑制MMP-9表达稳定动脉粥样锺化斑块．

Effect of Rosiglitazone on Serum MMP-9 Concentration and Expression of Peripheral Monocyte MMP-9 mRNA in Rats with Diabetes

Objective： To observe the effect of rosiglitazone on serum MMP-9 concentration and expression of peripheral monocyte MMP-9 in rats with diabetes. Method： Thirty SD rats were randomly divided into 3 groups： control group （n = 10）, diabetes group （n = 10） and rosiglitazone group （n = 10）. The rat diabetic model was made by the intraperitoneal injection of streptozocin. After the model was made successfully, the rats of rosiglitazone group were treated with rosiglitazone （5 mg·kg^-1 ·d^-1 for 28d） by gavage and the rats of control group and diabetes group were treated with normal saline. The concentration of serum MMP -9 were detected by Enzyme-linked Immunosorbent Assay （ELISA） . The expression of peripheral monocyte MMP-9 mRNA were measured by RT-PCR. Result： The concentration of serum MMP-9 were lowered by rosiglitazone treatment. The expression of peripheral monocyte MMP-9 mRNA were inhibited by rosiglitazone treatment too. Conclusion： Rosiglitazone may be stable artery atherosclerosis plaque through inhibit the mRNA expression of MMP-9.